<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From 1979 to 1988, 82 allogeneic and 2 syngeneic bone marrow transplants (BMT) were performed in 78 patients (age range 13-49 years) with the following diagnoses: <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (21 patients); <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (15 patients); <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> in <z:hpo ids='HP_0011010'>chronic</z:hpo>, accelerated, or <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-CP, AP or BC) (25 patients); <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (1 patient); <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) (1 patient); <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) (1 patient); diffuse poorly differentiated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DPDL) (1 patient); <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) (13 patients) </plain></SENT>
<SENT sid="1" pm="."><plain>Univariant analyses were carried out to determine factors of importance in predicting outcome </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients receiving transplants in remission had 12/19 (63%) survivors </plain></SENT>
<SENT sid="3" pm="."><plain>Only one of seven ALL patients receiving transplants in remission survives free of disease, and none of eight patients receiving transplants in relapse survived </plain></SENT>
<SENT sid="4" pm="."><plain>Six ALL patients relapsed </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:mp ids='MP_0005481'>CML</z:mp>, 6 of 16 (40%) patients receiving transplants in CP survive; two of nine patients (22%) in AP or BC survive </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 13 <z:hpo ids='HP_0001915'>aplastic anemias</z:hpo>, 8 (62%) survive </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-vs.-host disease</z:e> (GVHD) was evaluated in 75 patients, 24 of 33 (73%) who developed GVHD died, compared to 24 of 44 (55%) who did not develop GVHD </plain></SENT>
<SENT sid="8" pm="."><plain>Of the 30 patients given the combination of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) plus <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CSP), only 23% developed GVHD, compared to 58% of those not given the combination </plain></SENT>
<SENT sid="9" pm="."><plain>Interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (IP) occurred in 16 patients and was fatal in 15 </plain></SENT>
<SENT sid="10" pm="."><plain>The introduction of daily <z:chebi fb="4" ids="2453">acyclovir</z:chebi> and weekly intravenous gamma globulin in 1985 was associated with little reduction in the frequency of IP (from 20% to 18%) </plain></SENT>
<SENT sid="11" pm="."><plain>However, survival increased from 21% to 47%.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>